Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims:

Claims 1-70 (canceled)

Claim 71 (new): A method for inducing an antigen-specific immune response in a subject comprising:

a) pretreating an area of the skin of said subject; and

b) applying a formulation to said pretreated area, wherein said formulation comprises:

1) at least one antigen sufficient to induce an antigen-specific immune response;

2) at least one adjuvant present in an amount effective to induce said immune response to said at least one antigen; and,

3) a pharmaceutically acceptable carrier;

wherein said pretreating enhances said immune response.

Claim 72 (new): The method of claim 71, wherein said pretreating disrupts only the outer surface of said area of skin.

Claim 73 (new): The method of claim 71, wherein said pretreating comprises applying one or more chemicals.

Claim 74 (new): The method of claim 73, wherein said one or more chemicals are alcohols, acetones, detergents, depilatory agents, keratinolytic formulations, or combinations thereof.

Claim 75 (new): The method of claim 72, wherein said pretreating comprises using a device.

Claim 76 (new): The method of claim 75, wherein said device is selected from the group consisting of a propellant device, a device comprising tines, a device comprising microneedles, a device comprising a tine disk, a tape stripping device, a gas powered gun, a swab, an emory board, an abrasive pad, an electroporation device, an ultrasound device, and an iontophoresis device.

Claim 77 (new): The method of claim 76, wherein a patch comprises said device.

Claim 78 (new): The method of claim 71, wherein said antigen is derived from a pathogen.

Claim 79 (new): The method of claim 78, wherein said antigen is derived from an influenza virus.

Claim 80 (new): The method of claim 79, wherein said antigen is hemaglutinin A.

Claim 81 (new): The method of claim 80, wherein said antigen is derived from a bacteria.

Claim 82 (new): The method of claim 81, wherein said antigen is *E. coli* heat-labile enterotoxin (LT).

Claim 83 (new): The method of claim 71, wherein said adjuvant comprises a molecule selected from the group consisting of a bacterial ADP-ribosylating exotoxin (bARE), a binding B subunit of a bARE, and a toxoid of a bARE.

Claim 84 (new): The method of claim 71, wherein said antigen and said adjuvant are the same molecule.

Claim 85 (new): The method of claim 71, wherein the formulation is applied using a patch.

Claim 86 (new): A method for inducing an antigen-specific immune response in a subject comprising concurrently

a) treating an area of the skin of said subject; and

b) applying a formulation to said treated area, wherein said formulation comprises:

1) at least one antigen sufficient to induce an antigen-specific immune response;

2) at least one adjuvant present in an amount effective to induce said immune response to said at least one antigen; and,

3) a pharmaceutically acceptable carrier;

wherein said treating enhances said immune response.

Claim 87 (new): The method of claim 86, wherein said treating disrupts only the outer surface of said area of skin.

Claim 88 (new): The method of claim 86, wherein said treating comprises applying one or more chemicals.

Claim 89 (new): The method of claim 86, wherein said method comprises using a patch to concurrently treat said area of the skin and to apply said formulation.

Claim 90 (new): The method of claim 89, wherein said patch comprises a device that disrupts only the outer surface of said area of the skin.

Claim 91 (new): The method of claim 86, wherein said antigen is derived from a pathogen.

Claim 92 (new): The method of claim 86, wherein said antigen and said adjuvant are the

same molecule.

Claim 93 (new): The method of claim 86, wherein the formulation is applied using a patch.

Claim 94 (new): A method for inducing an antigen-specific immune response in a subject comprising:

a) applying a first formulation comprising at least one antigen at an area of the skin of said subject; and

b) applying a second formulation comprising at least one adjuvant at the same or different area of the skin as the first formulation, thereby inducing an antigen-specific immune response;

wherein said formulations are applied epicutaneously or by disrupting only the outer surface of said area of the skin.

Claim 95 (new): The method of claim 94, further comprising treating said area of the skin to enhance an immune response, wherein said treating disrupts only the outer surface of said skin site.

Claim 96 (new): The method of claim 95, wherein said area of the skin is treated prior to applying the first formulation, concurrently with applying the first formulation, or concurrently with applying the second formulation.

Claim 97 (new): The method of claim 96, wherein the first and second formulations are applied at the same time.

Claim 98 (new): The method of claim 96, wherein treating said area of the skin comprises applying one or more chemicals.

Claim 99 (new): The method of claim 96, wherein treating said area of the skin

comprises using a device.

Claim 100 (new): The method of claim 99, wherein said device is selected from the group consisting of a propellant device, a device comprising tines, a device comprising microneedles, a device comprising a tine disk, a tape stripping device, a gas powered gun, a swab, an emory board, an abrasive pad, an electroporation device, an ultrasound device, and an iontophoresis device.

Claim 101 (new): The method of claim 100, wherein said device is on a patch.

Claim 102 (new): The method of claim 94, wherein said antigen is derived from a pathogen.

Claim 103 (new): The method of claim 94, wherein said adjuvant comprises a molecule selected from the group consisting of a bacterial ADP-ribosylating exotoxin (bARE), a binding B subunit of a bARE, and a toxoid of a bARE.

Claim 104 (new): The method of claim 94, wherein said antigen and said adjuvant are the same molecule.

Claim 105 (new): The method of claim 94, wherein the method further comprises administering said antigen intramuscularly, orally, nasally, or parenterally.